JZP-110 + Placebo oral tablet
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Narcolepsy
Conditions
Narcolepsy
Trial Timeline
May 1, 2015 → Feb 1, 2017
NCT ID
NCT02348593About JZP-110 + Placebo oral tablet
JZP-110 + Placebo oral tablet is a phase 3 stage product being developed by Jazz Pharmaceuticals for Narcolepsy. The current trial status is completed. This product is registered under clinical trial identifier NCT02348593. Target conditions include Narcolepsy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02348606 | Phase 3 | Completed |
| NCT02348593 | Phase 3 | Completed |
Competing Products
20 competing products in Narcolepsy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| E2086 + E2086 Placebo + Active Comparator + Active Comparator Placebo | Eisai | Phase 1 | 33 |
| MK-6552 + Placebo | Merck | Phase 1 | 33 |
| Sodium Oxybate (Xyrem) | UCB | Phase 1 | 30 |
| JZP-110 + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| ADX-N05 + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| Xyrem | Jazz Pharmaceuticals | Phase 3 | 74 |
| JZP258 | Jazz Pharmaceuticals | Approved | 82 |
| ADX-N05 + Placebo | Jazz Pharmaceuticals | Phase 2 | 49 |
| Xyrem (sodium oxybate) oral solution | Jazz Pharmaceuticals | Phase 3 | 74 |
| JZP-258 | Jazz Pharmaceuticals | Approved | 82 |
| JZP441 + Matching Placebo | Jazz Pharmaceuticals | Phase 1 | 30 |
| Xyrem + Xyrem Placebo + Modafinil at established dose + Modafinil (Placebo) | Jazz Pharmaceuticals | Phase 3 | 74 |
| JZP-258 | Jazz Pharmaceuticals | Phase 3 | 74 |
| Transition from Xyrem to Xywav | Jazz Pharmaceuticals | Pre-clinical | 20 |
| JZP-110 | Jazz Pharmaceuticals | Phase 3 | 74 |
| Sunosi (solriamfetol) + Other prescription wake-promoting medications or stimulants | Axsome Therapeutics | Pre-clinical | 20 |
| AXS-12 (reboxetine) + Placebo | Axsome Therapeutics | Phase 3 | 74 |
| Solriamfetol 150 mg Oral Tablet | Axsome Therapeutics | Phase 1 | 30 |
| AXS-12 (Reboxetine) + Placebo | Axsome Therapeutics | Phase 2 | 49 |
| AXS-12 (reboxetine) + Placebo | Axsome Therapeutics | Phase 3 | 74 |